Navigation Links
EUPROBIO 2008 Presentation to Highlight Latest Immune Research
Date:10/6/2008

Presentation to focus on a new dietary supplement resulting from years of study by leading research scientists in Russia, Ukraine and Bulgaria,

Del-Immune V

BOULDER, Colo., Oct. 6 /PRNewswire/ -- On Thursday, October 16, 2008 at the EUPROBIO 2008 Conference, an abstract entitled "Immune regulatory cytokines Del-Immune V(R) induction and its impact on cytotoxicity of natural killer cells" will be presented to physicians, researchers and educators. Attendees to the presentation will learn about the latest advancements in this field of research. After seeing the study abstract, conference organizers made last-minute changes to the conference schedule to include a presentation of this groundbreaking research.

The abstract is based on a recent study focusing on Del-Immune V(R), a new immunomodulator containing DNA and peptoglycan fragments of lactobacillus rhamnosus V. The study, which confirms that this formulation enhances immune function, was conducted in the Ukraine by several of Europe's foremost research scientists.

Among other findings, the study demonstrated that daily administration of Del-Immune V(R) within 5 days raised a level of circulating interferon up to 4.2+/-0.5 log2 u/ml (P <0.05) against 2.0+/-0.3 log2 u/ml of the controls. Interferons are the switches that help cells resist viral infection and provide the initial, crucial immune response to immune challenges. The results of this latest research demonstrate the immune modulator activity of Del-Immune V(R) and the potential value the dietary supplement may have in clinical situations.

Del-Immune V(R) is a dietary supplement containing a natural culture that starts with healthy bacteria originally found in unpasteurized milk. Unique technological processing of the Del-Immune V(R) formulation creates a natural immunostimulant. The study described above and other research indicates that Del-Immune V(R) could be beneficial in assisting the body in its natural role of protecting the body from germs, viruses and other bodily invaders.

Del-Immune V(R) dietary supplements are produced in the United States. Thousands of people take Del-Immune V(R) on a regular basis and doctors have reported positive results, including an enhanced resistance to cold and flu and a restorative effect on the immune system.

The EUPROBIO 2008 Conference will be held October 15-18, 2008 in Cracow, Poland at Auditorium Maximum.

Contact:

Pamela Sichel

Pure Research Products, LLC

303-530-7761

http://www.delimmune.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Pure Research Products, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Strategic Diagnostics Updates Roth Conference Presentation Time
2. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
3. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
4. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
5. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
9. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
10. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
11. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):